Construction of Macaque Immune-Libraries. (Q47369432)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29116501%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

title

Construction of Macaque Immune-Libraries (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29116501%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29116501%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29116501%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Sebastian Miethe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29116501%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Thibaut Pelat

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29116501%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

language of work or name

English

0 references

publication date

1 January 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29116501%20AND%20SRC:MED&resulttype=core&format=json

Methods in Molecular Biology

9 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29116501%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

volume

1701

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29116501%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

page(s)

83-112

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29116501%20AND%20SRC:MED&resulttype=core&format=json

Continuous cultures of fused cells secreting antibody of predefined specificity

9 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Engineering of therapeutic antibodies to minimize immunogenicity and optimize function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Have we overestimated the benefit of human(ized) antibodies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Human antibody expression in transgenic rats: comparison of chimeric IgH loci with human VH, D and JH but bearing different rat C-gene regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Human antibody production in transgenic animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Phage display-derived human antibodies in clinical development and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Selecting and screening recombinant antibody libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

The role of phage display in therapeutic antibody discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Generation and analysis of the improved human HAL9/10 antibody phage display libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Human Monoclonal Fab Antibodies Against West Nile Virus and its Neutralizing Activity Analyzed in Vitro and in Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Rise and fall of an anti-MUC1 specific antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Evolutionary hypervariability in the hinge region of the immunoglobulin alpha gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Variable region gene segment utilization in rhesus monkey hybridomas producing human red blood cell-specific antibodies: predominance of the VH4 family but not VH4-21 (V4-34).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

A comparison of human and macaque (Macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Isolation of antibodies from non-human primates for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

The humanness of macaque antibody sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Development of Human-Like scFv-Fc Neutralizing Botulinum Neurotoxin E

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Isolation of Anti-Ricin Protective Antibodies Exhibiting High Affinity from Immunized Non-Human Primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

A human scFv antibody generation pipeline for proteome research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Mating antibody phage display with proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Phagemid vectors for phage display: properties, characteristics and construction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Antibodies to watch in 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Analyzing the "degree of humanness" of antibody sequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Rituximab: how approval history is reflected by a corresponding patent filing strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

Single chain Fab (scFab) fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7447-4_5

10.1007/978-1-4939-7447-4_5

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29116501%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29116501%20AND%20SRC:MED&resulttype=core&format=json